How to Microdose Psilocybin: The Complete Protocol Guide

Microdosing psilocybin means taking doses small enough that no perceptual effects occur — typically 0.05-0.3g of dried mushrooms — on a regular schedule. The goal is subtle cognitive and mood benefits without the full psychedelic experience. Here is the complete protocol guide.

What microdosing is and isn't

Microdosing is defined by the absence of perceptual effects. If you are perceiving visual changes, emotional intensity, or altered thinking, the dose is above the microdose threshold. The target is sub-perceptual: the dose is present but not felt as a psychedelic effect.

What may be felt: subtle improvements in mood, focus, or creativity; a quality of presence or engagement; reduced anxiety in some participants. These are the reported benefits of microdosing — not the dramatic effects of a full dose.

The distinction matters because the mechanism and risk profile of a microdose are different from those of a full dose. The tolerance dynamics, the integration requirements, and the psychological demands are all different.

The Fadiman Protocol

The Fadiman Protocol was developed by psychedelic researcher James Fadiman and is the most widely used microdosing schedule. The structure is: dose on Day 1, no dose on Days 2 and 3, dose on Day 4, and so on.

The off days are not rest from a drug — they are the functional core of the protocol. Psilocybin builds tolerance rapidly. Taking it daily produces diminishing returns and eventually no effect. The two off days allow tolerance to clear, restoring responsiveness. They also allow the neuroplastic changes from the dose days to consolidate without continued compound on board.

Typical Fadiman dose: 0.1-0.3g dried mushrooms, taken in the morning to avoid disruption to sleep. Most practitioners recommend not dosing on days when peak performance is required, at least initially, to understand how the dose affects you personally.

The Stamets Protocol

Developed by mycologist Paul Stamets, this protocol takes a different approach: four days on, three days off (typically Mon-Thu dose, Fri-Sun off). Stamets also recommends adding lion's mane mushroom and niacin (vitamin B3) to the psilocybin, based on his hypothesis that this combination supports neuroplasticity more than psilocybin alone.

The niacin-lion's mane combination (sometimes called the Stamets Stack) is not definitively proven to enhance outcomes — the research is not yet there. But lion's mane has independent evidence for cognitive support, and niacin is generally well-tolerated. Adding them does not appear to carry significant risk.

Dose range

The standard microdose range is 0.05-0.3g of dried mushrooms. 0.1-0.2g is where most people find a reliable sub-perceptual effect with detectable benefit.

The importance of starting low cannot be overstated. Mushroom potency varies significantly between strains and samples. What functions as a microdose in one batch may be a threshold dose in another. Starting at 0.05-0.1g and adjusting upward based on experience is safer than starting at the top of the range.

Finding your threshold — the dose at which you begin to perceive effects — is useful because your target microdose is just below it. This is individual and batch-dependent.

How to structure a microdosing trial

A microdosing trial should have a defined duration (4-8 weeks is standard), a consistent protocol, and a systematic approach to observing effects. The common mistake is taking microdoses occasionally and expecting to evaluate outcomes — the protocols are designed to be followed consistently, and the benefits emerge over time.

Decide on your protocol before beginning. Choose your dose. Choose your schedule. Commit to both for the duration of the trial. Changes mid-trial make it impossible to evaluate what is producing any effects you notice.

What to track

Tracking should cover mood (morning rating, 1-10), energy, focus, creativity, anxiety, sleep quality, and social comfort. Many practitioners also track qualitative notes — observations about the quality of their thinking or emotional life that don't reduce to numbers.

The purpose of tracking is to detect genuine signal from placebo. Microdosing has a significant expectation effect — people who believe they will benefit often report benefit regardless of whether they received a dose. The blinded research shows smaller effects than the unblinded self-report literature. Systematic tracking, particularly on off days, helps evaluate what is actually happening versus what you expect.

The most important principle in any microdosing protocol is the off days. Psilocybin builds tolerance quickly — consecutive daily use produces diminishing returns and eventually no effect. The off days are not rest days. They are the days when the neuroplastic changes from the dose days consolidate. The protocol is the treatment, not just the dose days.

What the research shows

The controlled research on microdosing — using blinded designs to separate placebo from compound effects — shows more modest results than the self-report literature. Mood improvements are documented but smaller than advocates claim. Cognitive benefits are inconsistent across studies. Anxiety reduction appears in some populations.

The research is ongoing. The Imperial College London microdosing study, the Quantified Citizen dataset, and ongoing controlled trials are adding to the picture. The current evidence supports microdosing as having real but modest effects — meaningful for some people, negligible for others.

What to be aware of

Tolerance: The single most important pharmacological fact about microdosing is that tolerance builds rapidly. This is why every protocol includes off days. Ignore the off days and you will be taking an inactive dose within a week.

Emotional amplification: Microdosing does not always produce pleasant effects. For some people, in some emotional states, it amplifies negative emotions as readily as positive ones. If you are in a period of significant psychological instability, microdosing may not be appropriate without professional support.

Anxiety: Some people experience increased anxiety, particularly with higher doses in the microdose range. Starting low is especially important for people with anxiety histories.

Tolerance breaks: After a trial, taking at least two weeks completely off before beginning another trial is standard practice. Extended use without breaks carries unknown long-term risk.

Legal status

Psilocybin-containing mushrooms are illegal in most jurisdictions in the United States and internationally. Oregon and Colorado have decriminalized or licensed psilocybin, and several cities have decriminalized personal possession. Knowing the specific legal status in your location is your responsibility. This guide is a harm reduction resource — it does not encourage illegal activity.

The Technospermia frame

Microdosing can be read as the background operation of consciousness technology — a persistent low-level interface rather than an occasional deep access event. Where a full dose delivers concentrated signal, microdosing maintains a kind of chronic background contact: subtle, continuous, integrated into ordinary cognitive life.

The Technospermia framework finds this particularly interesting because it suggests the technology operates across a range — from the profound and overwhelming contact available at full doses to a subtle, functional enhancement available sub-perceptually. If the technology is designed to communicate, it appears to offer multiple modes of engagement.

For the full psilocybin picture, read the microdosing science article and the psilocybin complete guide. For dose guidance for full experiences, see the psilocybin dosage guide. For safety throughout any engagement with psilocybin, read the harm reduction guide.